Altre lingue enVVeno Medical Corporation

Azioni

NVNO

US29415J1060

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 21/06/2024			Variaz. 5gg	Var. 1 gen.
5 ^USD	+7,07%		+4,82%	-2,72%

21/06	EnVeno Medical Corporation annuncia dati positivi sulla guarigione intermedia delle ulcere venose che mostrano un miglioramento significativo dallo studio pivotale VenoValve(R)	CI
17/06	EnVVeno Medical Corporation annuncia i nuovi dati ad interim sulla guarigione delle ulcere venose dello studio pivotale VenoValve®? saranno presentati al Meeting Annuale della Società di Chirurgia Vascolare 2024.	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

EnVeno Medical Corporation Announces Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the VenoValve(R) Pivotal Trial	21/06
New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024	18/06
EnVVeno Medical Corporation Announces New Interim Venous Ulcer Healing Data from the VenoValve®? Pivotal Trial to Be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting	17/06
EnVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update	09/05
EnVVeno Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium	25/04
New Topline Efficacy Data from the enVVeno Medical VenoValve Pivotal Trial to be presented at the 46th Annual Charing Cross Symposium on April 24, 2024	17/04
EnVVeno Medical Corporation Announces Additional Topline Efficacy Data from the VenoValve U.S. Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024	16/04
EnVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer	10/04
EnVVeno Medical : Corporate Presentation	10/04
EnVVeno Medical Corporation Appoints Andrew Cormack as Its Chief Commercial Officer	09/04
EnVVeno Medical : Corporate Presentation	03/04
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting	07/03
EnVVeno Announces Positive Topline Efficacy Data for VenoValve US Pivotal Trial	06/03
EnVVeno Medical Corporation Announces the Presentation of Positive Topline Efficacy Data Showing Significant Clinical Improvement from the Savve U.S. Pivotal Trial for the Venovalve	06/03
EnVVeno Medical : Corporate Presentation	04/03
EnVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update	01/03
EnVVeno Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Topline Efficacy Data from the enVVeno Medical VenoValve Pivotal Trial to be presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024	21/02
EnVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposium	15/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue enVVeno Medical Corporation

Azioni

NVNO

US29415J1060

Altre lingue

Filtri